Collectively, these data demonstrate that topobexin (9) inhibits TOP2B, which reduces anthracycline-induced DNA damage, apoptosis, and cell death in post-mitotic cardiomyocytes over a range of concentrations, but does not hinder the anticancer effect of DAU in HL-60 cancer cells. Here, TOP2B is linked to cancer.